

TILMOVET AC ORAL SOLUTION- tilmicosin phosphate concentrate
Huvepharma, Inc.

Tilmovet AC
(tilmicosin phosphate)
250 mg/ml tilmicosin

Front Panel

960 ml

Tilmovet® AC
(tilmicosin phosphate)
250 mg/ml tilmicosin

Aqueous concentrate for oral use in drinking water.

For swine only.

Macrolide Antibiotic.

Do not inject this product. Injection of tilmicosin has been shown to be fatal in swine and non-human primates, and may be fatal in horses and goats.

WARNING

Exposure to tilmicosin in humans has been associated with chest pain, increased heart rate, dizziness, headache, and nausea. Death has been reported following ingestion or injection of tilmicosin.

Avoid ingestion. Avoid direct skin and eye contact. In case of human exposure, call 1-877-994-4883 and consult a physician immediately.

NOTE TO THE PHYSICIAN:

The cardiovascular system is the target of toxicity and should be monitored closely. The primary cardiac effects are tachycardia and decreased contractility. Cardiovascular toxicity may be due to calcium channel blockade.

See User Safety Warnings for additional information.

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Read enclosed product information carefully for complete details.

Indications:

For the control of swine respiratory disease associated with *Pasteurella multocida* and *Haemophilus parasuis* in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

For the control of swine respiratory disease associated with *Mycoplasma hyopneumoniae* in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

Lot No.**Exp. Date****Dosage and Administration:**

Must be diluted before administration to animals. Include in the drinking water to provide a concentration of 200 mg tilmicosin per liter (200 ppm). One 960 ml bottle is sufficient to medicate 1200 liters (320 gallons) of drinking water for pigs. The medicated water should be administered for (5) five consecutive days.

Use within 24 hours of mixing with water. Do not use rusty containers for medicated water as they may affect product integrity.

When using a water medicating pump with a 1:128 inclusion rate, add 1 bottle (960 ml) of Tilmovet AC (tilmicosin phosphate) per 2.5 gallons of stock solution.

WARNINGS:**USER SAFETY WARNINGS:**

FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. SEE BOXED WARNING AND ENCLOSED PRODUCT INFORMATION (INCLUDING NOTE TO THE PHYSICIAN).

Wear overalls, impervious gloves and eye protection when mixing and handling the product. Wash hands after handling the product. Wash affected parts if skin contact occurs. If accidental eye contact occurs, immediately rinse thoroughly with water. To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Huvepharma, Inc. at 1-877-994-4883 or www.huvepharma.us. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at

<http://www.fda.gov/reportanimalae>.

RESIDUE WARNING:

Swine intended for human consumption must not be slaughtered within 7 days of the last treatment with this product.

Approved by FDA under ANADA # 200-707

960 ml

**Tilmovet® AC
(tilmicosin phosphate)
250 mg/ml tilmicosin**

Aqueous concentrate for oral use in drinking water.

For swine only.

Macrolide Antibiotic.

Do not inject this product. Injection of tilmicosin has been shown to be fatal in swine and non-human primates, and may be fatal in horses and goats.

WARNING

Exposure to tilmicosin in humans has been associated with chest pain, increased heart rate, dizziness, headache, and nausea. Death has been reported following ingestion or injection of tilmicosin.

Avoid ingestion. Avoid direct skin and eye contact. In case of human exposure, call 1-877-994-4883 and consult a physician immediately.

NOTE TO THE PHYSICIAN:

The cardiovascular system is the target of toxicity and should be monitored closely. The primary cardiac effects are tachycardia and decreased contractility. Cardiovascular toxicity may be due to calcium channel blockade.

See User Safety Warnings for additional information.

CAUTION:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Active Drug Ingredient: tilmicosin (as tilmicosin phosphate) 250 mg/ml

Description:

Tilmovet AC is a formulation of the antibiotic tilmicosin. Tilmicosin is produced semisynthetically and is in the macrolide class of antibiotics. Each milliliter (ml) of Tilmovet aqueous concentrate solution contains 250 mg of tilmicosin.

Indications:

For the control of swine respiratory disease associated with *Pasteurella multocida* and *Haemophilus parasuis* in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

For the control of swine respiratory disease associated with *Mycoplasma hyopneumoniae* in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

Dosage and Administration:

Must be diluted before administration to animals. Include in the drinking water to provide a concentration of 200 mg tilmicosin per liter (200 ppm). One 960 ml bottle is sufficient to medicate 1200 liters (320 gallons) of drinking water for pigs. The medicated water should be administered for (5) five consecutive days.

Use within 24 hours of mixing with water. Do not use rusty containers for medicated water as they may affect product integrity.

When using a water medicating pump with a 1:128 inclusion rate, add 1 bottle (960 ml) of Tilmovet AC (tilmicosin phosphate) per 2.5 gallons of stock solution.

WARNINGS:**USER SAFETY WARNINGS:**

FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. SEE BOXED WARNING AND ENCLOSED PRODUCT INFORMATION (INCLUDING NOTE TO THE PHYSICIAN).

Wear overalls, impervious gloves and eye protection when mixing and handling the product. Wash

hands after handling the product. Wash affected parts if skin contact occurs. If accidental eye

contact occurs, immediately rinse thoroughly with water. To report suspected adverse drug events,

for technical assistance or to obtain a copy of the Safety Data Sheet, contact

Huvepharma, Inc. at
1-877-994-4883 or www.huvepharma.us. For additional information about adverse drug
experience
reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at
<http://www.fda.gov/reportanimalae>.

RESIDUE WARNING:

Swine intended for human consumption must not be slaughtered within 7 days of the last treatment with this product.

Note to the Physician:

The cardiovascular system is the target of toxicity and should be monitored closely. Cardiovascular toxicity may be due to calcium channel blockade. In dogs, administration of intravenous calcium offset tilmicosin-induced tachycardia and negative inotropy (decreased contractility). Dobutamine partially offset the negative inotropic effects induced by tilmicosin injection in dogs. β -adrenergic antagonists, such as propranolol, exacerbated the negative inotropy of tilmicosin injection in dogs. Epinephrine potentiated lethality of tilmicosin injection in pigs. This antibiotic persists in tissues for several days.

Precautions:

Do not allow horses or other equines access to water containing tilmicosin. The safety of tilmicosin has not been established in male swine intended for breeding purposes.

Always treat the fewest number of animals necessary to control a respiratory disease outbreak. Prescriptions shall not be refilled. Concurrent use of Tilmovet AC (tilmicosin phosphate) and another macrolide by any route is not advised. Use of another macrolide immediately following this use of Tilmovet AC is not advised.

Adverse Reactions in Animals:

Decreased water consumption was observed in healthy pigs administered tilmicosin in target animal safety studies.

Ensure that pigs have continuous access to medicated water during the treatment period. Monitor pigs for signs of water refusal and dehydration while being treated. If decreased water consumption occurs, replace the medicated drinking water with fresh nonmedicated water and contact your veterinarian.

Clinical Pharmacology:

Tilmicosin is a macrolide antibiotic with *in vitro* antibacterial activity primarily against Gram-positive bacteria, although certain Gram-negative bacteria are also susceptible. Macrolides interfere with bacterial protein synthesis by reversibly binding to the 50S subunit of the ribosome. They are typically regarded as being bacteriostatic, but at high concentrations can be bactericidal. When administered orally to pigs via the drinking water, tilmicosin is rapidly absorbed and slowly eliminated from the body. Tilmicosin distributes rapidly to the target tissues. Detectable levels are found in lung tissue as early as 6 hours and peak at about 5 days after the commencement of treatment. The relationship of serum tilmicosin concentration to lung tilmicosin concentration or the concentrations in bronchial secretion has not been determined. In addition, the extent to which total lung concentrations represent free (active) drug has not been defined. Therefore, no conclusions can be made with regard to the clinical relevance of elevated tilmicosin concentrations in the lung. Tilmicosin has been shown to concentrate within alveolar macrophages. It is also found at fairly high concentrations in liver and kidney tissue, as it is excreted both via the bile into the feces and also via the urine.

Effectiveness:

The effectiveness of tilmicosin phosphate for the control of SRD associated with *P. multocida* and *H. parasuis* was confirmed in a natural infection field study across six U.S. sites. A total of 960 commercial-type grower pigs were enrolled and assigned to the tilmicosin-treated group (200 mg tilmicosin/L in drinking water for 5 consecutive days), or a non-medicated control group.

Pigs that 1) were found dead and were diagnosed with SRD, or 2) had a depression score and a respiratory score ≥ 2 (on a scale from 0 [normal] to 3 [severe]) and a rectal temperature of ≥ 104.5 °F were considered clinically affected.

At each site, treatments were initiated when at least 15% of the pigs were classified as clinically affected. After the 5-day treatment period and a 4-day post-treatment period, pigs were evaluated for treatment success (respiration and depression scores of 1 or 0 and rectal temperature < 104.5 °F), and were euthanized and evaluated for lung lesions.

A significantly higher ($p = 0.0118$) success rate (based on back-transformed least squares means) was detected for the

tilmicosin-treated group (275/473, 58.64%) compared to the control group (230/475, 47.89%).

The effectiveness of tilmicosin phosphate for the control of SRD associated with *M. hyopneumoniae* in the presence of PRRSV was confirmed in an induced infection model study. A total of 340 commercial-type pigs were enrolled and challenged with *M. hyopneumoniae* (single infection) or *M. hyopneumoniae* and PRRSV (co-infection). When necropsied sentinel pigs had at least 5% lung lesion involvement, study pigs were treated with tilmicosin phosphate (200 mg tilmicosin/L in drinking water) or non-medicated water for 5 consecutive days. After the 5 day treatment period and a 4 day post-treatment period, pigs were euthanized and evaluated for lung lesions.

For both the single infection and co-infection groups, the lung lesion percentage was statistically significantly different ($p=0.005$ and $p=0.0004$, respectively) in favor of the tilmicosin phosphate-treated group (21.01% and 31.74%, respectively) compared with the control group (28.26% and 43.04%, respectively).

Animal Safety:

A pharmacokinetic study was conducted to evaluate tilmicosin phosphate solution in pigs. The results were compared to pharmacokinetic data generated with tilmicosin phosphate Type A medicated article (NADA 141-064). The data demonstrates that blood and tissue levels of tilmicosin when administered to pigs at 200 mg/L (ppm) in water were consistently lower than when tilmicosin was administered to pigs at 181 g/ton (200 ppm) in feed.

A target animal safety study was conducted to evaluate the tolerance of tilmicosin phosphate solution in pigs when administered in drinking water.

Twenty pigs were administered medicated water at 0, 200, 400, or 600 mg/ L (0, 1X, 2X, or 3X the labeled dose) for 5 consecutive days or 200 mg/ L for 10 consecutive days. No treatment-related lesions were observed in any animals at necropsy. Water consumption was decreased in all tilmicosin-treated groups compared to the non-medicated group. One pig in the 600 mg/ L group was euthanized due to decreased water consumption, neurological signs attributed to severe dehydration, and subsequent refusal to drink non-medicated water. Two pigs in the 400 mg/ L group had reduced water intake and displayed mild clinical signs attributed to dehydration. One pig recovered after being offered non-medicated water. The second pig completed the treatment regimen without intervention.

Hydration and water consumption were evaluated during the control of SRD effectiveness field study.

Tilmicosin was administered to study pigs in drinking water at 200 mg/l for 5 consecutive days. There was no statistically significant difference in water consumption between tilmicosin-treated pigs and pigs receiving nonmedicated water. A subset of study pigs (20 tilmicosin treated pigs and 20 non-medicated pigs) were evaluated for hydration via a physical examination and analysis of blood samples for hematocrit, total protein, creatinine, and blood urea nitrogen. There were no abnormal physical examination findings or clinically relevant differences in clinical pathology variables between tilmicosin-treated pigs and pigs receiving nonmedicated water.

How Supplied:

Tilmovet AC (tilmicosin phosphate) is provided in a 960 ml white-colored plastic bottle sealed with a plastic screw cap.

Storage Conditions:

Store at or below 25° C (77° F). Excursions permitted to 40° C (104° F). Protect from direct sunlight.

Restricted Drug (California) - Use Only as Directed Approved by FDA under ANADA # 200-707

Manufactured For:
Huvepharma, Inc.
525 Westpark Drive, Suite 230
Peachtree City, GA 30269

Huvepharma and Tilmovet are registered trademarks of Huvepharma EOOD.

Front Panel

960 ml
Tilmovet® AC
tilmicosina como fosfato
(250 mg/ml tilmicosina)

Concentrado acuoso para uso oral en el agua de consumo.
Para ganado porcine únicamente.
Antibiótico macrólido.

No inyecte este producto. Se demostró que la inyección de tilmicosina es fatal para el ganado porcino y en primates no humanos, y podría ser fatal para caballos y cabras.

ADVERTENCIA

La exposición humana a la tilmicosina ha sido asociada con dolor en el pecho, aumenta de la frecuencia cardíaca, mareo, dolor de cabeza y náuseas. Se ha informado de fallecimientos tras la ingestión o inyección de la tilmicosina.

Evite su ingestión. Evite el contacto directo con la piel y los ojos. En caso de que ocurra alguna exposición humana, llame al 1-877-994-4883 y consulte inmediatamente con el médico.

NOTA PARA EL MÉDICO:

El sistema cardiovascular es el objetivo de la toxicidad y debe controlarse atentamente. Los efectos cardíacos principales son taquicardia y una disminución de la contractilidad. La toxicidad cardiovascular puede deberse al bloqueo de los canales de calcio.

Examine las Advertencias de seguridad para el usuario para obtener información adicional.

PRECAUCIÓN:

Las leyes federales establecen que el uso de este fármaco se restrinja a veterinarios con licencia o bajo la indicación de estos.

Lea cuidadosamente la información del producto que se adjunta para conocer los detalles completos.

Indicaciones:

para el control de la enfermedad respiratoria porcina asociada con *Pasteurella multocida* y *Haemophilus parasuis* en grupos de cerdos de establecimientos en las que se diagnostica un brote de enfermedad respiratoria.

Para el control de la enfermedad respiratoria porcina asociada con *Mycoplasma hyopneumoniae*

en la presencia del virus del síndrome reproductivo y respiratorio porcino (Porcine Reproductive and Respiratory Syndrome Virus, PRRSV) en grupos de cerdos en edificios donde se diagnostica un brote de enfermedad respiratoria.

Lot:

Exp.

Posología y administración:

se debe diluir antes de administrarse a los animales. Incluir en el agua de consumo para proporcionar una concentración de 200 mg de tilmicosina por litro (200 ppm). Un frasco de 960 ml es suficiente para medicar 1200 litros (320 galones) de agua de consumo para cerdos. El agua medicada debería administrarse durante 5 (cinco) días consecutivos. Usar dentro de las 24 horas de mezclarlo con agua. No use recipientes oxidados para el agua medicada, ya que los mismos podrían afectar la integridad del producto.

Si se usa una bomba de medicación de agua con una tasa de inclusión de 1:128, agregar 1 frasco (960 ml) de Tilmovet AC (tilmicosina como fosfato) por cada 2.5 galones de solución concentrada.

ADVERTENCIAS:

ADVERTENCIAS DE SEGURIDAD PARA EL USUARIO:

PARA SU USO EN ANIMALES ÚNICAMENTE. ESTE PRODUCTO NO DEBE UTILIZARSE EN SERES HUMANOS. MANTENGAFUERA DEL ALCANCE DE LOS NIÑOS. EXAMINE LA ADVERTENCIA PRESENTE EN LA CAJA Y LA INFORMACIÓN DEL PRODUCTO QUE SE ADJUNTA (INCLUIDA LA NOTA PARA EL MÉDICO). Use monos de trabajo, guantes impermeables y protección ocular al mezclar y manipular el producto. Lávese las manos después de manipular el producto. Lave las partes afectadas en caso de producirse el contacto con la piel. Si se produce contacto accidental con los ojos, inmediatamente enjuague bien con agua.

Para informar sospechas de eventos adversos del fármaco, recibir asistencia técnica u obtener una copia de la obtener asistencia técnica o una hoja de datos de seguridad (Safety Data Sheet, SDS), comuníquese con Huvepharma, Inc. al 1-877-994-4883 o www.huvepharma.us. Para obtener información adicional sobre la experiencia farmacológica adversa para la presentación de informes de fármacos para animales, comuníquese con la FDA al 1-888-FDA-VETS, o en línea en www.fda.gov/reportanimalae.

ADVERTENCIA ACERCA DE RESIDUOS:

los cerdos para consumo humano no se deberán faenar dentro de los 7 días posteriores al último tratamiento con este producto.

Aprobado por la FDA bajo ANADA # 200-707

960 ml
Tilmovet® AC
tilmicosina como fosfato
(250 mg/ml tilmicosina)

Concentrado acuoso para uso oral en el agua de consumo.
Para ganado porcino únicamente.
Antibiótico macrólido.

No inyecte este producto. Se demostró que la inyección de tilmicosina es fatal para el ganado porcino y en primates no humanos, y podrá ser fatal para caballos y cabras.

ADVERTENCIA

La exposición humana a la tilmicosina ha sido asociada con dolor en el pecho, aumenta de la frecuencia cardíaca, mareo, dolor de cabeza y náuseas. Se ha informado de fallecimientos tras la ingestión o inyección de la tilmicosina.

Evite su ingestión. Evite el contacto directo con la piel y los ojos. En caso de que ocurra alguna exposición humana, llame al 1-877-994-4883 y consulte inmediatamente con el médico.

NOTA PARA EL MÉDICO:

El sistema cardiovascular es el objetivo de la toxicidad y debe controlarse atentamente. Los efectos cardíacos principales son taquicardia y una disminución de la contractilidad. La toxicidad cardiovascular puede deberse al bloqueo de los canales de calcio. Examine las Advertencias de seguridad para el usuario para obtener información adicional.

PRECAUCIÓN:

Las leyes federales establecen que el uso de este fármaco se restrinja a veterinarios con licencia o bajo la indicación de estos.

Ingrediente fármaco activo: tilmicosina (como fosfato de tilmicosina) 250 mg/ml

Descripción:

Tilmovet AC es una formulación del antibiótico tilmicosina. La tilmicosina se produce en forma semisintética y pertenece a la clase de antibióticos macrólidos. Cada mililitro (ml) de solución de concentrado acuoso Tilmovet contiene 250 mg de tilmicosina.

Indicaciones:

para el control de la enfermedad respiratoria porcina asociada con *Pasteurella multocida*

y
Haemophilus parasuis en grupos de cerdos de establecimientos en los que se
diagnostica
un brote de enfermedad respiratoria.

Para el control de la enfermedad respiratoria porcina asociada con *Mycoplasma hyopneumoniae* en la presencia del virus del síndrome reproductivo y respiratorio porcino (Porcine Reproductive and Respiratory Syndrome Virus, PRRSV) en grupos de cerdos en edificios donde se diagnostica un brote de enfermedad respiratoria.

Posología y administración:

se debe diluir antes de administrarse a los animales. Incluir en el agua de consumo para proporcionar una concentración de 200 mg de tilmicosina por litro (200 ppm). Un frasco de 960 ml es suficiente para medicar 1200 litros (320 galones) de agua de consumo para cerdos. El agua medicada debería administrarse durante 5 (cinco) días consecutivos. Usar dentro de las 24 horas de mezclarlo con agua. No use recipientes oxidados para el agua medicada, ya que los mismos podrían afectar la integridad del producto.

Si se usa una bomba de medicación de agua con una tasa de inclusión de 1:128, agregar 1 frasco (960 ml) de Tilmovet AC (tilmicosina como fosfato) por cada 2.5 galones de solución concentrada.

ADVERTENCIAS:

ADVERTENCIAS DE SEGURIDAD PARA EL USUARIO:

PARA SU USO EN ANIMALES ÚNICAMENTE. ESTE PRODUCTO NO DEBE UTILIZARSE EN SERES HUMANOS. MANTENGAFUERA DEL ALCANCE DE LOS NIÑOS. EXAMINE LA ADVERTENCIA PRESENTE EN LA CAJA Y LA INFORMACIÓN DEL PRODUCTO QUE SE ADJUNTA (INCLUIDA LA NOTA PARA EL MÉDICO). Use monos de trabajo, guantes impermeables y protección ocular al mezclar y manipular el producto. Lávese las manos después de manipular el producto. Lave las partes afectadas en caso de producirse el contacto con la piel. Si se produce contacto accidental con los ojos, inmediatamente enjuague bien con agua.

Para informar sospechas de eventos adversos del fármaco, recibir asistencia técnica u obtener una copia de la obtención de asistencia técnica o una hoja de datos de seguridad (Safety Data Sheet, SDS), comuníquese con Huvepharma, Inc. al 1-877-994-4883 o www.huvepharma.us. Para obtener información adicional sobre la experiencia farmacológica adversa para la presentación de informes de fármacos para animales, comuníquese con la FDA al 1-888-FDA-VETS, o en línea en www.fda.gov/reportanimalae.

ADVERTENCIA ACERCA DE RESIDUOS:

los cerdos para consumo humano no se deberán faenar dentro de los 7 días

posteriores
al último tratamiento con este producto.

Nota para el médico:

El sistema cardiovascular es el objetivo de la toxicidad y debe controlarse atentamente. La toxicidad cardiovascular puede deberse al bloqueo de los canales de calcio. En los perros, la administración de calcio por vía intravenosa contrarresta la taquicardia inducida por la tilmicosina y el inotropismo negativo (disminución de la contractilidad). La dobutamina contrarresta parcialmente los efectos inotrópicos negativos inducidos por la tilmicosina en perros. Los antagonistas β adrenérgicos, como el propranolol, exacerbaron el inotropismo negativo de la inyección de tilmicosina en perros. La epinefrina potenció la letalidad de la inyección de tilmicosina en cerdos. Este antibiótico persiste en los tejidos durante varios días.

Precauciones:

No permita que caballos u otros equinos accedan al agua que contiene tilmicosina. No se ha establecido la seguridad de la tilmicosina en cerdos machos que se usan con fines de reproducción.

Trate siempre el menor número de animales necesario para controlar un brote de enfermedad respiratoria. Las recetas no deben renovarse.

No se recomienda el uso simultáneo de Tilmovet AC (tilmicosina como fosfato) y otro macrólido por cualquier vía de administración. No se recomienda el uso de otro macrólido inmediatamente después de este uso de Tilmovet AC.

Reacciones adversas en animales:

se observó una disminución en el consumo de agua en cerdos saludables a los que se administró tilmicosina en estudios de seguridad en animales objetivo. Asegúrese de que los cerdos tengan acceso constante al agua medicada durante el período de tratamiento. Controle que los cerdos no presenten signos de rechazo al agua y deshidratación mientras se las esté tratando. Si se produce una disminución en el consumo de agua, reemplace el agua de consumo medicada por agua potable sin medicar y comuníquese con su veterinario.

Presentación:

Tilmovet AC se proporciona en botellas de plástico, color blanco de 960 ml selladas con tapas plásticas con rosca.

Condiciones de almacenamiento:

Almacenar a o menos 25° C (77° F). Excursiones permitidas a 40° C (104° F).

Proteger de la luz solar directa.

Fármaco restringido (California). Usar únicamente según las indicaciones.

Aprobado por la FDA bajo ANADA # 200-707




Fabricado por:

Huvepharma, Inc.

525 Westpark Drive, Suite 230

Peachtree City, GA 30269, EE. UU.

Huvepharma y Tilmovet son marcas registradas propiedad a Huvepharma EOOD.

 <p>960 ml Tilmovet[®] AC (tilmicosin phosphate) 250 mg/ml tilmicosin</p> <p>Aqueous concentrate for oral use in drinking water. For swine only. Macrolide Antibiotic. Do not inject this product. Injection of tilimicosin has been shown to be fatal in swine and non-human primates, and may be fatal in horses and goats.</p> <p>WARNING Exposure to tilimicosin in humans has been associated with chest pain, increased heart rate, dizziness, headache, and nausea. Death has been reported following ingestion or injection of tilimicosin. Avoid ingestion. Avoid direct skin and eye contact. In case of human exposure, call 1-877-994-4883 and consult a physician immediately.</p> <p>NOTE TO THE PHYSICIAN: The cardiovascular system is the target of toxicity and should be monitored closely. The primary cardiac effects are tachycardia and decreased contractility. Cardiovascular toxicity may be due to calcium channel blockade. See User Safety Warnings for additional information.</p> <p>CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Read enclosed product information carefully for complete details.</p> <p>Indications: For the control of swine respiratory disease associated with <i>Pasteurella multocida</i> and <i>Haemophilus parasuis</i> in groups of swine in buildings where a respiratory disease outbreak is diagnosed. For the control of swine respiratory disease associated with <i>Mycoplasma hyopneumoniae</i> in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.</p>  <p>lot No. Exp. Date</p>	<p>Page 2</p> <p>Dosage and Administration: Must be diluted before administration to animals. Include in the drinking water to provide a concentration of 200 mg tilimicosin per liter (200 ppm). One 960 ml bottle is sufficient to medicate 1200 liters (320 gallons) of drinking water for pigs. The medicated water should be administered for (5) five consecutive days. Use within 24 hours of mixing with water. Do not use rusty containers for medicated water as they may affect product integrity. When using a water medicating pump with a 1:128 inclusion rate, add 1 bottle (960 ml) of Tilmovet AC (tilmicosin phosphate) per 2.5 gallons of stock solution.</p> <p>WARNINGS: USER SAFETY WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. SEE BOXED WARNING AND ENCLOSED PRODUCT INFORMATION (INCLUDING NOTE TO THE PHYSICIAN). Wear overalls, impervious gloves and eye protection when mixing and handling the product. Wash hands after handling the product. Wash affected parts if skin contact occurs. If accidental eye contact occurs, immediately rinse thoroughly with water. To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Huvepharma, Inc. at 1-877-994-4883 or www.huvepharma.us. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/reportanimalae.</p> <p>RESIDUE WARNING: Swine intended for human consumption must not be slaughtered within 7 days of the last treatment with this product.</p> <p>Approved by FDA under ANADA # 200-707</p> 
---	--

Tilmovet[®] AC 960 ml
(tilmicosin phosphate)
250 mg/ml tilmicosin

Aqueous concentrate for oral use in drinking water. For swine only. Macrolide Antibiotic. Do not inject this product. Injection of tilmicosin has been shown to be fatal in swine and non-human primates, and may be fatal in horses and goats.

WARNING

Exposure to tilmicosin in humans has been associated with chest pain, increased heart rate, dizziness, headache, and nausea. Death has been reported following ingestion or injection of tilmicosin. Avoid ingestion. Avoid direct skin and eye contact. In case of human exposure, call 1-877-994-4883 and consult a physician immediately.

NOTE TO THE PHYSICIAN:

The cardiovascular system is the target of toxicity and should be monitored closely. The primary cardiac effects are tachycardia and decreased contractility. Cardiovascular toxicity may be due to calcium channel blockade.

See User Safety Warnings for additional information.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Active Drug Ingredient: tilmicosin (as tilmicosin phosphate) 250 mg/ml

Description: Tilmovet AC is a formulation of the antibiotic tilmicosin. Tilmicosin is produced semi-synthetically and is in the macrolide class of antibiotics. Each milliliter (mL) of Tilmovet aqueous concentrate solution contains 250 mg of tilmicosin.

Indications: For the control of swine respiratory disease associated with *Pasteurella multocida* and *Haemophilus parasuis* in groups of swine in buildings where a respiratory disease outbreak is diagnosed. For the control of swine respiratory disease associated with *Mycoplasma hyopneumoniae* in the presence of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in groups of swine in buildings where a respiratory disease outbreak is diagnosed.

Dosage and Administration: Must be diluted before administration to animals. Include in the drinking water to provide a concentration of 200 mg tilmicosin per liter (200 ppm). One 960 ml bottle is sufficient to medicate 1200 liters (320 gallons) of drinking water for pigs. The medicated water should be administered for (5) five consecutive days.

Use within 24 hours of mixing with water. Do not use rusty containers for medicated water as they may affect product integrity.

When using a water medicating pump with a 1:128 inclusion rate, add 1 bottle (960 ml) of Tilmovet AC (tilmicosin phosphate) per 2.5 gallons of stock solution.

WARNINGS:

USER SAFETY WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. SEE BOXED WARNING AND NOTE TO THE PHYSICIAN FOR ADDITIONAL INFORMATION. Wear overalls, impervious gloves and eye protection when mixing and handling the product. Wash hands after handling the product. Wash affected parts if skin contact occurs. If accidental eye contact occurs, immediately rinse thoroughly with water. To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet, contact Hovepharm, Inc. at 1-877-994-4883 or www.hovepharm.us. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at <http://www.fda.gov/reportanimal>.

RESIDUE WARNING: Swine intended for human consumption must not be slaughtered within 7 days of the last treatment with this product.

Note to the Physician:

The cardiovascular system is the target of toxicity and should be monitored closely. Cardiovascular toxicity may be due to calcium channel blockade. In dogs, administration of intravenous calcium offset tilmicosin-induced tachycardia and negative inotropy (decreased contractility). Dobutamine partially offset the negative inotropic effects induced by tilmicosin injection in dogs. β -adrenergic antagonists, such as propranolol, exacerbated the negative inotropy of tilmicosin injection in dogs. Epinephrine potentiated lethality of tilmicosin injection in pigs. This antibiotic persists in tissues for several days.

Precautions:

Do not allow horses or other equines access to water containing tilmicosin. The safety of tilmicosin has not been established in male swine intended for breeding purposes.

Always treat the fewest number of animals necessary to control a respiratory disease outbreak. Prescriptions shall not be refilled. Concurrent use of tilimovet AC (tilmicosin phosphate) and another macrolide by any route is not advised. Use of another macrolide immediately following this use of tilimovet AC is not advised.

Adverse Reactions in Animals: Decreased water consumption was observed in healthy pigs administered tilimicosin in target animal safety studies. Ensure that pigs have continuous access to medicated water during the treatment period. Monitor pigs for signs of water refusal and dehydration while being treated. If decreased water consumption occurs, replace the medicated drinking water with fresh non-medicated water and contact your veterinarian.

Clinical Pharmacology: Tilimicosin is a macrolide antibiotic with *in vitro* antibacterial activity primarily against Gram-positive bacteria, although certain Gram-negative bacteria are also susceptible. Macrolides interfere with bacterial protein synthesis by reversibly binding to the 50S subunit of the ribosome. They are typically regarded as being bacteriostatic, but at high concentrations can be bactericidal. When administered orally to pigs via the drinking water, tilimicosin is rapidly absorbed and slowly eliminated from the body. Tilimicosin distributes rapidly to the target tissues. Detectable levels are found in lung tissue as early as 6 hours and peak at about 5 days after the commencement of treatment. The relationship of serum tilimicosin concentration to lung tilimicosin concentration or the concentrations in bronchial secretion has not been determined. In addition, the extent to which total lung concentrations represent free (active) drug has not been defined. Therefore, no conclusions can be made with regard to the clinical relevance of elevated tilimicosin concentrations in the lung. Tilimicosin has been shown to concentrate within alveolar macrophages. It is also found at fairly high concentrations in liver and kidney tissue, as it is excreted both via the bile into the feces and also via the urine.

Effectiveness: The effectiveness of tilimicosin phosphate for the control of SRD associated with *P. multocida* and *M. porosus* was confirmed in a natural infection field study across six U.S. sites. A total of 960 commercial-type grower pigs were enrolled and assigned to the tilimicosin-treated group (200 mg tilimicosin/L in drinking water for 5 consecutive days), or a non-medicated control group.

Pigs that 1) were found dead and were diagnosed with SRD, or 2) had a depression score and a respiratory score ≥ 2 (on a scale from 0 [normal] to 3 [severe]) and a rectal temperature of $\geq 104.5^\circ\text{F}$ were considered clinically affected. At each site, treatments were initiated when at least 15% of the pigs were classified as clinically affected. After the 5-day treatment period and a 4-day post-treatment period, pigs were evaluated for treatment success (respiration and depression scores of 1 or 0 and rectal temperature $< 104.5^\circ\text{F}$), and were euthanized and evaluated for lung lesions. A significantly higher ($p = 0.0118$) success rate (based on back-transformed least squares means) was detected for the tilimicosin-treated group (275/475, 58.64%) compared to the control group (230/475, 47.89%).

The effectiveness of tilimicosin phosphate for the control of SRD associated with *M. hyopneumoniae* in the presence of PRRSV was confirmed in an induced infection model study. A total of 340 commercial-type pigs were enrolled and challenged with *M. hyopneumoniae* (single infection) or *M. hyopneumoniae* and PRRSV (co-infection). When necropsied sentinel pigs had at least 5% lung lesion involvement, study pigs were treated with tilimicosin phosphate (200 mg tilimicosin/L in drinking water) or non-medicated water for 5 consecutive days. After the 5-day treatment period and a 4-day post-treatment period, pigs were euthanized and evaluated for lung lesions.

For both the single infection and co-infection groups, the lung lesion percentage was statistically significantly different ($p=0.005$ and $p=0.0004$, respectively) in favor of the tilimicosin phosphate-treated group (21.01% and 31.74%, respectively) compared with the control group (28.26% and 43.04%, respectively).

Animal Safety: A pharmacokinetic study was conducted to evaluate tilimicosin phosphate solution in pigs. The results were compared to pharmacokinetic data generated with tilimicosin phosphate Type A medicated article (NADA 141-064). The data demonstrates that blood and tissue levels of tilimicosin when administered to pigs at 200 mg/L (ppm) in water were consistently lower than when tilimicosin was administered to pigs at 181 g/ton (200 ppm) in feed.

A target animal safety study was conducted to evaluate the tolerance of tilimicosin phosphate solution in pigs when administered in drinking water.

Twenty pigs were administered medicated water at 0, 200, 400, or 600 mg/l (0, 1X, 2X, or 3X the labeled dose) for 5 consecutive days or 200 mg/l for 10 consecutive days. No treatment-related lesions were observed in any animals at necropsy. Water consumption was decreased in all tilimicosin-treated groups compared to the non-medicated group. One pig in the 600 mg/l group was euthanized due to decreased water consumption, neurological signs attributed to severe dehydration, and subsequent refusal to drink non-medicated water. Two pigs in the 400 mg/l group had reduced water intake and displayed mild clinical signs attributed to dehydration. One pig recovered after being offered non-medicated water, the second pig completed the treatment regimen without intervention.

Hydration and water consumption were evaluated during the control of 500 effectiveness field study. Tilimicosin was administered to study pigs in drinking water at 200 mg/l for 5 consecutive days. There was no statistically significant difference in water consumption between tilimicosin-treated pigs and pigs receiving non-medicated water. A subset of study pigs (20 tilimicosin-treated pigs and 20 non-medicated pigs) were evaluated for hydration via a physical examination and analysis of blood samples for hematocrit, total protein, creatinine, and blood urea nitrogen. There were no abnormal physical examination findings or clinically relevant differences in clinical pathology variables between tilimicosin-treated pigs and pigs receiving non-medicated water.

How Supplied: Tilmovet AC (tilimicosin phosphate) is provided in a 560 ml white-colored plastic bottle sealed with a plastic screw cap.

Storage Conditions: Store at or below 25° C (77° F). Excursions permitted to 40° C (104° F). Protect from direct sunlight.

Restricted Drug (California) - Use Only as Directed Approved by FDA under ANADA # 200-707

Manufactured For:
Huvepharma, Inc.
525 Westpark Drive, Suite 230
Peachtree City, GA 30269

Huvepharma and Tilmovet are registered trademarks of Huvepharma E000.

TILMOVET AC ORAL SOLUTION

tilmicosin phosphate concentrate

Product Information

Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC:23243-7287
Route of Administration	Oral		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
TILMICOSIN PHOSPHATE (UNII: SMH7U1S683) (TILMICOSIN - UNII:XL4103X2E3)	TILMICOSIN PHOSPHATE	250 mg in 1 mL

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:23243-7287-1	960 mL in 1 BOTTLE		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANADA	ANADA200707	01/25/2022	

Labeler - Huvepharma, Inc. (619153559)

Revised: 1/2022

Huvepharma, Inc.